Skip to main content
Top
Published in: Clinical Rheumatology 6/2017

01-06-2017 | Brief Report

Assessment of six cardiovascular risk calculators in Mexican mestizo patients with rheumatoid arthritis according to the EULAR 2015/2016 recommendations for cardiovascular risk management

Authors: Dionicio A. Galarza-Delgado, Jose R. Azpiri-Lopez, Iris J. Colunga-Pedraza, Jesus A. Cardenas-de la Garza, Raymundo Vera-Pineda, Griselda Serna-Peña, Rosa I. Arvizu-Rivera, Adrian Martinez-Moreno, Martin Wah-Suarez, Mario A. Garza Elizondo

Published in: Clinical Rheumatology | Issue 6/2017

Login to get access

Abstract

Variability of the 10-year cardiovascular (CV) risk predicted by the Framingham Risk Score (FRS) using lipids, FRS using body mass index (BMI), Reynolds Risk Score (RRS), QRISK2, Extended Risk Score—Rheumatoid Arthritis (ERS-RA), and algorithm developed by the American College of Cardiology and the American Heart Association in 2013 (ACC/AHA 2013) according to the European League Against Rheumatism (EULAR) 2015/2016 update of its evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis (RA) has not been evaluated in Mexican mestizo patients. CV risk was predicted using six different risk calculators in 116 patients, aged 40–75, who fulfilled the ACR/EULAR 2010 classification criteria. Results were multiplied by 1.5 according to the EULAR 2015/2016 update. Global comparison of the risk predicted by all scales was done using the Friedman test, considering a P value of ≤0.05 as statistically significant. Individual comparison between the algorithms was made using the Wilcoxon signed-rank test, and a P value of ≤0.003 was considered statistically significant. All calculators showed to be different in the Friedman test (p ≤ 0.001). Median values of predicted 10-year CV risk were 11.02% (6.18–17.55) for FRS BMI; 8.47% (4.6–13.16) for FRS lipids; 5.55% (2.5–11.85) for QRISK2; 5% (3.1–8.65) for ERS-RA; 3.6% (1.5–9.3) for ACC/AHA 2013; and 1.5% (1.5–4.5) for RRS. ERS-RA showed no difference when compared against QRISK2 (p = 0.269). CV risk calculators showed variability among them and cannot be used indistinctly in RA-patients.
Literature
2.
go back to reference Peters M, Symmons D, McCarey D, Dijkmans B, Nicola P, Kvien T et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325–331CrossRefPubMed Peters M, Symmons D, McCarey D, Dijkmans B, Nicola P, Kvien T et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325–331CrossRefPubMed
3.
go back to reference Pieringer H, Pichler M (2011) Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications. QJM 104:13–26CrossRefPubMed Pieringer H, Pichler M (2011) Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications. QJM 104:13–26CrossRefPubMed
4.
go back to reference Sarmiento-Monroy JC, Amaya-Amaya J, Espinosa-Serna JS, Herrera-Díaz C, Anaya J-M, Rojas-Villarraga A (2012) Cardiovascular disease in rheumatoid arthritis: a systematic literature review in Latin America. Arthritis 2012:371909CrossRefPubMedPubMedCentral Sarmiento-Monroy JC, Amaya-Amaya J, Espinosa-Serna JS, Herrera-Díaz C, Anaya J-M, Rojas-Villarraga A (2012) Cardiovascular disease in rheumatoid arthritis: a systematic literature review in Latin America. Arthritis 2012:371909CrossRefPubMedPubMedCentral
5.
go back to reference Barber CE, Smith A, Esdaile JM, Barnabe C, Martin LO, Faris P et al (2015) Best practices for cardiovascular disease prevention in rheumatoid arthritis: a systematic review of guideline recommendations and quality indicators. Arthritis Care Res (Hoboken) 67:169–179CrossRef Barber CE, Smith A, Esdaile JM, Barnabe C, Martin LO, Faris P et al (2015) Best practices for cardiovascular disease prevention in rheumatoid arthritis: a systematic review of guideline recommendations and quality indicators. Arthritis Care Res (Hoboken) 67:169–179CrossRef
6.
go back to reference Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M (2014) Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford) 53:2143–2154CrossRef Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M (2014) Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford) 53:2143–2154CrossRef
7.
go back to reference Solomon DH, Greenberg J, Curtis JR, Liu M, Farkouh M, Tsao P et al (2015) Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a consortium of rheumatology researchers of North America registry study. Arthritis Rheumatol 67:1995–2003CrossRefPubMed Solomon DH, Greenberg J, Curtis JR, Liu M, Farkouh M, Tsao P et al (2015) Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a consortium of rheumatology researchers of North America registry study. Arthritis Rheumatol 67:1995–2003CrossRefPubMed
8.
go back to reference Agca R, Heslinga S, Rollefstad S, Heslinga M, McInnes I, Peters M, et al. (2016) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis [journal on the internet]. 2013 Oct 3[date cited 2013 Dec 7]. doi:10.1136/annrheumdis-2016-209775 Agca R, Heslinga S, Rollefstad S, Heslinga M, McInnes I, Peters M, et al. (2016) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis [journal on the internet]. 2013 Oct 3[date cited 2013 Dec 7]. doi:10.​1136/​annrheumdis-2016-209775
9.
go back to reference D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM et al (2008) General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation 117:743–753CrossRefPubMed D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM et al (2008) General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation 117:743–753CrossRefPubMed
10.
go back to reference Ridker PM, Buring JE, Rifai N, Cook NR (2007) Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA 297:611–619CrossRefPubMed Ridker PM, Buring JE, Rifai N, Cook NR (2007) Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA 297:611–619CrossRefPubMed
11.
go back to reference Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A et al (2008) Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 336:1475–1482CrossRefPubMedPubMedCentral Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A et al (2008) Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 336:1475–1482CrossRefPubMedPubMedCentral
12.
go back to reference Arts E, Popa C, Den Broeder A, Semb A, Toms T, Kitas G et al (2014) Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis 74:668–674CrossRefPubMed Arts E, Popa C, Den Broeder A, Semb A, Toms T, Kitas G et al (2014) Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis 74:668–674CrossRefPubMed
13.
go back to reference Crowson CS, Matteson EL, Roger VL, Therneau TM, Gabriel SE (2012) Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol 110:420–424CrossRefPubMedPubMedCentral Crowson CS, Matteson EL, Roger VL, Therneau TM, Gabriel SE (2012) Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol 110:420–424CrossRefPubMedPubMedCentral
14.
go back to reference Damen JA, Hooft L, Schuit E, Debray TP, Collins GS, Tzoulaki I et al (2016) Prediction models for cardiovascular disease risk in the general population: systematic review. BMJ 353:i2416CrossRefPubMedPubMedCentral Damen JA, Hooft L, Schuit E, Debray TP, Collins GS, Tzoulaki I et al (2016) Prediction models for cardiovascular disease risk in the general population: systematic review. BMJ 353:i2416CrossRefPubMedPubMedCentral
15.
go back to reference Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R et al (2014) 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 129:S49–S73CrossRefPubMed Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R et al (2014) 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 129:S49–S73CrossRefPubMed
16.
go back to reference Guardado-Estrada M, Juarez-Torres E, Medina-Martinez I, Wegier A, Macías A, Gomez G et al (2009) A great diversity of Amerindian mitochondrial DNA ancestry is present in the Mexican mestizo population. J Hum Genet 54:695–705CrossRefPubMed Guardado-Estrada M, Juarez-Torres E, Medina-Martinez I, Wegier A, Macías A, Gomez G et al (2009) A great diversity of Amerindian mitochondrial DNA ancestry is present in the Mexican mestizo population. J Hum Genet 54:695–705CrossRefPubMed
17.
go back to reference Turesson C, Jacobsson L, Bergström U (1999) Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology (Oxford) 38:668–674CrossRef Turesson C, Jacobsson L, Bergström U (1999) Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology (Oxford) 38:668–674CrossRef
18.
go back to reference González-Gay MA, González-Juanatey C (2014) Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox. Ann Rheum Dis 73:1281–1283CrossRefPubMed González-Gay MA, González-Juanatey C (2014) Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox. Ann Rheum Dis 73:1281–1283CrossRefPubMed
19.
go back to reference Alcocer LA, Lozada O, Fanghänel G, Sánchez-Reyes L, Campos-Franco E (2011) Estratificación del riesgo cardiovascular global. Comparación de los métodos Framingham y SCORE en población mexicana del estudio PRIT. Cir Cir 79:168–174PubMed Alcocer LA, Lozada O, Fanghänel G, Sánchez-Reyes L, Campos-Franco E (2011) Estratificación del riesgo cardiovascular global. Comparación de los métodos Framingham y SCORE en población mexicana del estudio PRIT. Cir Cir 79:168–174PubMed
20.
go back to reference Mosca L, Barrett-Connor E, Kass Wenger N (2011) Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation 124:2145–2154CrossRefPubMedPubMedCentral Mosca L, Barrett-Connor E, Kass Wenger N (2011) Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation 124:2145–2154CrossRefPubMedPubMedCentral
21.
go back to reference Catapano AL, Reiner Z, De Backer G (2011) European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemias the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217:3–46CrossRefPubMed Catapano AL, Reiner Z, De Backer G (2011) European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemias the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217:3–46CrossRefPubMed
22.
go back to reference Dessein PH, Corrales A, Lopez-Mejias R, Solomon A, Woodiwiss AJ, Llorca J et al (2016) The Framingham score and the systematic coronary risk evaluation at low cutoff values are useful surrogate markers of high-risk subclinical atherosclerosis in patients with rheumatoid arthritis. J Rheumatol 43:486–494CrossRefPubMed Dessein PH, Corrales A, Lopez-Mejias R, Solomon A, Woodiwiss AJ, Llorca J et al (2016) The Framingham score and the systematic coronary risk evaluation at low cutoff values are useful surrogate markers of high-risk subclinical atherosclerosis in patients with rheumatoid arthritis. J Rheumatol 43:486–494CrossRefPubMed
Metadata
Title
Assessment of six cardiovascular risk calculators in Mexican mestizo patients with rheumatoid arthritis according to the EULAR 2015/2016 recommendations for cardiovascular risk management
Authors
Dionicio A. Galarza-Delgado
Jose R. Azpiri-Lopez
Iris J. Colunga-Pedraza
Jesus A. Cardenas-de la Garza
Raymundo Vera-Pineda
Griselda Serna-Peña
Rosa I. Arvizu-Rivera
Adrian Martinez-Moreno
Martin Wah-Suarez
Mario A. Garza Elizondo
Publication date
01-06-2017
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 6/2017
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-017-3551-7

Other articles of this Issue 6/2017

Clinical Rheumatology 6/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine